Please select the option that best describes you:
Which PARP inhibitor do you recommend for maintenance therapy in BRCA+ ovarian cancer after primary chemotherapy and why?
How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?
Answer from: at Community Practice
Given the abundance of both efficacy and safety data available for Olaparib in this setting, I use Olaparib for maintenance therapy in BRCA+ ovarian cancer patients after primary chemotherapy. The 5-year PFS data from SOLO-1, confirming sustained benefit beyond the end of treatment, further sp...
Sign in or Register to read more
Answer from: at Academic Institution
Either olaparib or niraparib. I most commonly start with olaparib, as this has the most favorable toxicity profile. If not tolerated even after dose adjustments, I would consider switching to niraparib.
Answer from: at Academic Institution
Use the one you are comfortable using. They are otherwise equally as efficacious.